en · de · es · fr · pt
peptide-index.peptides1004.com › Data › Ipamorelin Background And Receptor Pharmacology — Hands-On Walkthrough

Ipamorelin Background And Receptor Pharmacology — Hands-On Walkthrough

By Editorial Desk · published 2026-03-11 · last reviewed 2026-03-28 · Data

certificate of analysis raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2026-03-28. Anything still debated is marked as such rather than presented as settled.

Ipamorelin Background and Receptor Pharmacology

Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.

In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.

Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.

Background and Structural Identity

Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.

Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.

The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.

Ipamorelin at a glance

PropertyValueNotes
Peptide classSynthetic pentapeptideGHS-R1a agonist family
Receptor targetGhrelin receptor (GHS-R1a)G-protein-coupled receptor
Sequence lengthFive amino acid residuesIncludes non-natural residues
Primary reported outputPulsatile growth hormone releaseObserved in animal and early human work
Molecular formulaC38H49N9O5Corresponds to roughly 711.9 g/mol

Handling, Stability and Analytical Verification

Reversed-phase high-performance liquid chromatography is the standard tool for assessing purity. Detection near 214 nanometers captures the peptide backbone, and the resulting chromatogram shows the main peak alongside related impurities. Electrospray ionization mass spectrometry confirms molecular mass and supports sequence verification. Common degradation products include oxidized residues, deamidated forms, and truncated fragments, each appearing as a distinct peak or shoulder in the trace.

Quality claims for research peptides vary widely across suppliers. A certificate of analysis should list purity by chromatography, the mass found by spectrometry, and the analytical conditions used. Independent testing at a third-party laboratory is a common way to check identity and purity, because documents alone cannot confirm what is inside a vial. Purity figures describe the proportion of the target peptide among detected species, and they say nothing about biological activity or sterility.

Related pages on this site

Supporting material

=== Purifications and measurements of mass === The minimum molecular weight suggested by Mulder's analyses was roughly 9 kDa, hundreds of times larger than other molecules being studied. Hence, the chemical structure of proteins (their primary structure) was an active area of research until 1949, when Fred Sanger sequenced insulin. The (correct) theory that proteins were linear polymers of amino acids linked by peptide bonds was proposed independently and simultaneously by Franz Hofmeister and Emil Fischer at the same conference in 1902. However, some scientists were sceptical that such long macromolecules could be stable in solution. Consequently, numerous alternative theories of the protein primary structure were proposed, e.g., the colloidal hypothesis that proteins were assemblies of small molecules, the cyclol hypothesis of Dorothy Wrinch, the diketopiperazine hypothesis of Emil Abderhalden and the pyrrol/piperidine hypothesis of Troensgard (1942). Most of these theories had difficulties in accounting for the fact that the digestion of proteins yielded peptides and amino acids. Proteins were finally shown to be macromolecules of well-defined composition (and not colloidal mixtures) by Theodor Svedberg using analytical ultracentrifugation. The possibility that some proteins are non-covalent associations of such macromolecules was shown by Gilbert Smithson Adair (by measuring the osmotic pressure of hemoglobin) and, later, by Frederic M. Richards in his studies of ribonuclease S.

== Plasma proteins == Plasma contains a large variety of proteins including albumin, immunoglobulins, and clotting proteins such as fibrinogen. Albumin constitutes about 60% of the total protein in plasma and is present at concentrations between 35 and 55 mg/mL. It is the main contributor to osmotic pressure of the blood and it functions as a carrier molecule for molecules with low water solubility such as lipid-soluble hormones, enzymes, fatty acids, metal ions, and pharmaceutical compounds. Albumin is structurally stable due to its seventeen disulfide bonds and unique in that it has the highest water solubility and the lowest isoelectric point (pI) of the plasma proteins. Due to the structural integrity of albumin it remains stable under conditions where most other proteins denature.

Patch A consists of the positively charged residues 3,4 and 5, patch B of residues 10, 12, 13 and the N-terminus (including possible salt bridges between Lys10 and Glu12 and Asp13 and the N-terminus), and patch C of 19, 40, 41 and the C-terminus.

{\displaystyle {\begin{aligned}{\frac {\mathbf {D} m}{\mathbf {Dt} }}&={\iiint \limits _{V}}\left({{\frac {\mathbf {D} \rho }{\mathbf {Dt} }}+\rho (\nabla \cdot \mathbf {u} )}\right)dV\\{\frac {\mathbf {D} \rho }{\mathbf {Dt} }}+\rho (\nabla \cdot {\mathbf {u} })&={\frac {\partial \rho }{\partial t}}+({\nabla \rho })\cdot {\mathbf {u} }+{\rho }(\nabla \cdot \mathbf {u} )={\frac {\partial \rho }{\partial t}}+\nabla \cdot ({\rho \mathbf {u} })=0\end{aligned}}}

=== Asia === Bangladesh: The Ministry of Foreign Affairs issued a statement expressing concern over the "recent developments in Venezuela", and that "diplomacy and dialogue should prevail to solve all disputes between countries and reaffirms steadfast commitment to the fundamental principles of the UN Charter and international law." China: The Ministry of Foreign Affairs said that it was "deeply shocked and strongly condemns the U.S. for recklessly using force against a sovereign state and targeting its president" and that the attack "seriously violate[d] international law, violate[d] Venezuela's sovereignty, and threaten[ed] the peace and security of Latin America and the Caribbean". The ministry urged on the U.S. to release Maduro and his wife and ensure their personal safety. The statement was made despite US president Donald Trump telling Fox News a few hours prior to the strikes that China would not take issue with the operation due to his good relationship with Chinese leader Xi Jinping. The Chinese Embassy in Venezuela advised Chinese citizens to avoid travel to Venezuela due to the security situation. Foreign minister Wang Yi stated that "We never believe that any country can play the role of world policeman, nor do we agree that any country can claim itself to be an international judge." He also stated that China opposes the use or threat of force.

Sources: en.wikipedia.org

Notes from published material

== Commercialization == There are several liposome medicines currently available commercially, which helps set the regulatory pathway for immunoliposome therapies. As immunoliposome therapy has progressed in research, big market players in pharmaceutical research and manufacturing have invested in the development of these therapies. A relevant example of this is a phase I/II trial that examined the effectiveness of PDS0101 in combination with pembrolizumab, an immune checkpoint inhibitor (sold under the brand name Keytruda). The study is funded by PDS Biotechnology and in partnership with Merck. The purpose of the study is to determine the effectiveness of PDS0101 + pembrolizumab in shrinking tumors in patients with virus-related oropharyngeal cancer tumors in humans. PDS0101 is a peptide-based vaccine that aids in the immune response to kill tumor cells. The study also relies on pembrolizumab monoclonal antibodies to help the body's immune system attack the cancer and interfere with the spread of tumor cells. Although immunoliposome therapy exhibits clinical and commercial promise, there are several known challenges in the translation from laboratory studies to clinical studies and ultimately to commercialization. One obstacle is that immunoliposome therapy is limited by having a short half-life and retention time once it reaches the tumor microenvironment. Additionally, immunoliposome therapies are often individualized which requires close clinical monitoring and comprehensive evaluation methods.

Mass spectrometry Macromolecular crystallography Neutron diffraction Proteolysis Nuclear magnetic resonance spectroscopy of proteins (NMR) Electron paramagnetic resonance (EPR) Cryogenic electron microscopy (cryoEM) Electron crystallography and microcrystal electron diffraction Multiangle light scattering Small angle scattering Ultrafast laser spectroscopy Anisotropic terahertz microspectroscopy Two-dimensional infrared spectroscopy Dual-polarization interferometry and circular dichroism Most often researchers use them to study the "native states" of macromolecules. But variations on these methods are also used to watch nascent or denatured molecules assume or reassume their native states. See protein folding. A third approach that structural biologists take to understanding structure is bioinformatics to look for patterns among the diverse sequences that give rise to particular shapes. Researchers often can deduce aspects of the structure of integral membrane proteins based on the membrane topology predicted by hydrophobicity analysis. See protein structure prediction.

Erowid.org – PCP Information National Institute of Drug Abuse InfoFacts: PCP (Phencyclidine) Archived 2012-01-06 at the Wayback Machine Drugs and Human Performance Fact Sheets on Phencyclidine Phencyclidine and Ketamine: A View From the Street-1981 article on the use and effects of PCP; Archived 2019-01-21 at the Wayback Machine "Phencyclidine". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on May 7, 2021.

The New York Times wrote that Biden's "weak filters make him capable of blurting out pretty much anything". According to The New York Times, Biden often embellishes elements of his life or exaggerates, a trait also noted by The New Yorker in 2014. For instance, he has claimed to have been more active in the civil rights movement than he actually was, and has falsely recalled being an excellent student who earned three college degrees. The Times wrote, "Mr. Biden's folksiness can veer into folklore, with dates that don't quite add up and details that are exaggerated or wrong, the factual edges shaved off to make them more powerful for audiences."

Sources: en.wikipedia.org

Background from the literature

== Two-dimensional IR == Two-dimensional infrared correlation spectroscopy analysis combines multiple samples of infrared spectra to reveal more complex properties. By extending the spectral information of a perturbed sample, spectral analysis is simplified and resolution is enhanced. The 2D synchronous and 2D asynchronous spectra represent a graphical overview of the spectral changes due to a perturbation (such as a changing concentration or changing temperature) as well as the relationship between the spectral changes at two different wavenumbers.

1 January – New Year's Day 16–17 February – Carnival 3 April – Good Friday 21 April – Tiradentes's Day 1 May – Labour Day 4 June – Feast of Corpus Christi 7 September – Independence Day 12 October – Our Lady of Aparecida 2 November – All Souls' Day 15 November – Republic Day 20 November – Black Consciousness Day 25 December – Christmas Day 31 December — New Year's Eve

== Intentional == DNA fragmentation is often necessary prior to library construction or subcloning for DNA sequences. A variety of methods involving the mechanical breakage of DNA have been employed where DNA is fragmented by laboratory personnel. Such methods include sonication, needle shear, nebulisation, point-sink shearing and passage through a pressure cell.

=== Names === Leuprorelin is the generic name of the drug and its INNTooltip International Nonproprietary Name and BANTooltip British Approved Name, while leuprorelin acetate is its BANMTooltip British Approved Name and JANTooltip Japanese Accepted Name, leuprolide acetate is its USANTooltip United States Adopted Name and USPTooltip United States Pharmacopeia, leuprorelina is its DCITTooltip Denominazione Comune Italiana, and leuproréline is its DCFTooltip Dénomination Commune Française. It is also known by its developmental code names A-43818, Abbott-43818, DC-2-269, and TAP-144. Leuprorelin is marketed by Bayer AG under the brand name Viadur, by Tolmar under the brand names Eligard and Fensolvi, and by TAP Pharmaceuticals (1985–2008), by Varian Pharmed( Previously named Varian Darou Pajooh) under the brand name Leupromer and Abbott Laboratories (2008–present) under the brand name Lupron.

intercalating agent Any chemical compound (e.g. ethidium bromide) that disrupts the alignment and pairing of bases in the complementary strands of a DNA molecule by inserting itself between the bases.

Sources: en.wikipedia.org

Frequently asked questions

What is ipamorelin classified as?

It is a synthetic pentapeptide in the growth hormone secretagogue family and acts as an agonist at the ghrelin receptor. It is handled as a laboratory research compound rather than a naturally occurring hormone.

Does ipamorelin release only growth hormone?

Studies generally report growth hormone as the dominant output, with smaller or absent effects on adrenocorticotropic hormone and prolactin. The size of that separation depends on the assay and the dose examined, so it is best described as relative selectivity.

Is the compound naturally present in the body?

No natural source has been identified, and the molecule is produced by chemical synthesis. Its non-natural residues distinguish it from endogenous ghrelin even though both engage the same receptor.

What type of molecule is ipamorelin?

It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.

Network